Skip to main content

20th International Myeloma Workshop Main banner

QoL and Patient-Reported Outcome and Supportive Care

QoL and Patient-Reported Outcome and Supportive Care

Type here to filter the list

P-449: Role of Education and Empowerment in Multiple Myeloma patients
P-450: Comparison of a battery powered device (OnControl) versus manual Jamshidi needle for bone marrow biopsy in adult patients with plasma cell disorders: A prospective randomized control trial (RCT)
P-451: Association between Dexamethasone Exposure and Visually Significant Cataracts in Myeloma
P-452: Financial Toxicity and Time Toxicity among Patients with Multiple Myeloma
P-453: Randomized Phase II Study of Digital Life Coaching during Stem Cell Transplantation for Myeloma
P-454: Patients views on the relevance of Quality of Life (QoL) Questionnaires commonly applied to evaluate the QoL of patients with AL Amyloidosis
P-455: Survey of Multiple Myeloma (MM) patients and Healthcare Professionals (HCPs) on the relevance of existing Health Quality-of-Life (QoL) Questionnaires (QoLQ) to real-world QoL issues of MM patients
P-456: Survey on real world Quality of Life (QoL) issues relevant to distinct AL Amyloidosis patient subgroups
P-457: Waldenstrom’s Macroglobulinaemia (WM) patients’ online survey -Currently available QoLQs not representative of Real-world Health Quality-of-Life (QoL) issues of WM patients
P-458: The impact of continuous therapy on the Quality of Life in Romanian patients with Multiple Myeloma
P-459: A Randomized, Controlled Phase 2 Trial of Uproleselan, an E-Selectin Inhibitor, vs Placebo to Reduce GI Toxicity in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
P-460: Evaluation of a precision-based exercise program for patients with Multiple Myeloma
P-461: An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses
P-462: Free Light Chain Ratio over 100 and Risk of Hemodialysis in Multiple Myeloma
P-463: Patient Characteristics and Burden in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey
P-464: Treatment Decision-Making in Patients Diagnosed With Multiple Myeloma
P-465: Global Disparities in Multiple Myeloma: Examining Adverse Events and Drug Toxicity Trends
P-466: PERIPHERAL AND SEVERE AUTONOMIC NEUROPATHY CHARACTERIZED BY DIZZINESS, ORTHOSTATIC HYPOTENSION AND WEIGHT LOSS CAUSED BY BORTEZOMIB.
P-467: Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse National Health and Nutrition Examination Survey (NHANES) case-control study
P-468: Risk of Secondary Primary Malignancies after Multiple Myeloma in the Novel Therapy Era : A Nationwide Case-Control Cohort Study
P-469: Observational study of COVID-19 prophylactic antibody (Tixagevimab/Cilgavimab) administration for multiple myeloma patients
P-470: Single center experience of denosumab for hypercalcemia in multiple myeloma
P-471: The MMRF Cure Cloud research study: a real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys
P-472: Evaluation of the usefulness of the QuantiFERON-TB Gold In-Tube test for the detection of latent Mycobacterium tuberculosis infections in patients underwent autologous stem cell transplantation
P-473: Real-world evidence of Statins and Oral Antidiabetics for Multiple Myeloma
P-474: The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to BCMA-Directed Therapies: Results from the MagnetisMM-3 Study
P-475: Are we downplaying toxicity with our choice of words? A systematic review of randomized myeloma trials.
P-476: More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial
P-477: PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA IN THE OMICRON SARS-COV-2 ERA
P-478: Humanistic, Clinical, and Economic Burden in Patients with Relapsed or Refractory Multiple Myeloma on Second Line or Higher Therapy: A Systematic Literature Review
P-479: Disparities in Clinical Trial Enrolment and Survival Outcomes by Socio-economic Class in Multiple Myeloma
P-480: Outcome of Pneumocystis jirovecii pneumonia in patients with multiple myeloma
P-481: The effect of touch on pain, anxiety and the patient experience during bone marrow biopsies
P-482: Dietary habits correlate with myeloma pathogenesis and treatment outcome in multiple myeloma
P-483: A Whole Foods Plant-based Weight Loss Intervention Improves Metabolic and Immune Biomarkers in MGUS/SMM Patients as well as Progression Trajectory in a Subset – The NUTRIVENTION Trial
P-484: Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias.
P-485: Novel Observation of the Negative Effects of Persistent Chronic Opioid Use on Myeloma Survival: A Retrospective Urban-Based Cohort Study and Ongoing Prospective HealthTree Survey Study
P-486: Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
P-487: Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with Multiple Myeloma in outpatient care:
A longitudinal observational study
P-488: Expert in the Loop - AI assisted generation of Real-World-Evidence
P-489: Prolonged cytopenia after CAR T-cell therapy in multiple myeloma: results from a prospective comprehensive biomarker study
P-500: MULTIPLE MYELOMA: Do we have scales to assess the risk of Thromboembolic Events (TEV)?
P-501: EHA GUIDELINES FOR THE USE AND REPORTING OF PATIENT-REPORTED OUTCOMES IN MULTIPLE MYELOMA CLINICAL TRIALS